DRIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DarioHealth Corp (DRIO) is not a good buy for a beginner, long-term investor at this time. The stock exhibits weak technical indicators, declining financial performance, and lacks strong positive catalysts. Additionally, hedge funds are selling, and analysts have lowered price targets citing limited visibility on revenue growth and profitability. Given the investor's preference for long-term stability, it is better to wait for clearer signs of growth and momentum before considering this stock.
The technical indicators for DRIO are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 39.328, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 6.543 and resistance at 7.823.
The gross margin increased to 65.09%, up 17.79% YoY, indicating some operational efficiency improvements.
Hedge funds are selling the stock, with a 109.67% increase in selling over the last quarter. Analysts have lowered the price target from $16 to $10, citing limited visibility on revenue growth and profitability. Financial performance shows a significant YoY revenue drop (-31.21%) and a widened net loss (-37531469). No recent news or congress trading data is available to suggest positive momentum.
In Q4 2025, revenue dropped by 31.21% YoY to $5,231,000. Net income increased to -$37,531,469 (up 206.10% YoY), indicating a larger loss. EPS dropped by 63.34% YoY to -1.14. However, gross margin improved to 65.09%, up 17.79% YoY.
Stifel lowered the price target from $16 to $10 while maintaining a Buy rating. The firm highlights limited visibility on revenue growth acceleration and profitability, which is unlikely to regain momentum in the near term.
